These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6275567)

  • 1. Some biochemical activities of 10,10-difluoro-13-dehydroprostacyclin, a chemically stable analog of prostacyclin, in human blood platelets.
    Harris DN; Phillips MB; Michel IM; Goldenberg HJ; Haslanger MF; Antonaccio MJ; Fried J
    Thromb Res; 1981 Aug 15-Sep 1; 23(4-5):387-99. PubMed ID: 6275567
    [No Abstract]   [Full Text] [Related]  

  • 2. Aggregation and thromboxane formation by platelets and vascular prostacyclin production from BB rats. An animal model for type I diabetes.
    Landgraf-Leurs MM; Landgraf R; Loy A; Weber PC; Herberg LL
    Prostaglandins; 1982 Jul; 24(1):35-46. PubMed ID: 6812171
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation.
    Haslam RJ; Rosson GM
    Mol Pharmacol; 1975 Sep; 11(5):528-44. PubMed ID: 170501
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclic adenosine 3',5'-monophosphate and prostacyclin inhibit membrane phospholipase activity in platelets.
    Lapetina EG; Schmitges CJ; Chandrabose K; Cuatrecases P
    Biochem Biophys Res Commun; 1977 Jun; 76(3):828-35. PubMed ID: 197928
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets.
    Tateson JE; Moncada S; Vane JR
    Prostaglandins; 1977 Mar; 13(3):389-97. PubMed ID: 191877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
    Ruppert D; Weithmann KU
    Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ticlopidine on platelet prostaglandin metabolism. Possible consequences for prostacyclin production.
    Lagarde M; Ghazi I; Dechavanne M
    Prostaglandins Med; 1979 Jun; 2(6):433-9. PubMed ID: 399526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of circulating prostacyclin.
    Haslam RJ; McClenaghan MD
    Nature; 1981 Jul; 292(5821):364-6. PubMed ID: 7019720
    [No Abstract]   [Full Text] [Related]  

  • 9. Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidil.
    Mazurov AV; Menshikov MYu ; Leytin VL; Tkachuk VA; Repin VS
    FEBS Lett; 1984 Jul; 172(2):167-71. PubMed ID: 6086387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandins E1 and E2, but neither prostacyclin nor prostaglandin D2 have anti-aggregating activity in chicken blood.
    Bult H; Wechsung E; Houvenaghel A; Herman AG
    Arch Int Pharmacodyn Ther; 1981 Feb; 249(2):306-8. PubMed ID: 7013724
    [No Abstract]   [Full Text] [Related]  

  • 11. The antagonism of prostaglandins I2, E1 and D2 by prostaglandin E2 in human platelets.
    Bonne C; Martin B; Watada M; Regnault F
    Thromb Res; 1981 Jan 1-15; 21(1-2):13-22. PubMed ID: 6262942
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
    Eggerman TL; Harker LA; Andersen NH; Wilson CH
    Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG2) in human platelets.
    Malmsten C; Granström E; Samuelsson B
    Biochem Biophys Res Commun; 1976 Jan; 68(2):569-76. PubMed ID: 175797
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets.
    Best LC; Martin TJ; Russell RG; Preston FE
    Nature; 1977 Jun; 267(5614):850-2. PubMed ID: 197414
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostacyclin: its biosynthesis, actions, and clinical potential.
    Dusting GJ; Moncada S; Vane JR
    Adv Prostaglandin Thromboxane Leukot Res; 1982; 10():59-106. PubMed ID: 6216790
    [No Abstract]   [Full Text] [Related]  

  • 16. Modulation of human platelet function by prostacyclin and thromboxane A2.
    Gorman RR
    Fed Proc; 1979 Jan; 38(1):83-8. PubMed ID: 215465
    [No Abstract]   [Full Text] [Related]  

  • 17. A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.
    O'Grady J; Hedges A; Whittle BJ; Al-Sinawi LA; Mekki QA; Burke C; Moody SG; Moti MJ; Hassan S
    Br J Clin Pharmacol; 1984 Dec; 18(6):921-33. PubMed ID: 6085004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DN.9693, a phosphodiesterase inhibitor, compared with prostaglandin E1 and prostacyclin in four platelet "function" tests.
    O'Brien JR; Etherington MD; Salmon GP
    Thromb Res; 1988 Apr; 50(1):237-41. PubMed ID: 2840751
    [No Abstract]   [Full Text] [Related]  

  • 19. New vistas on the role of platelets in bronchoconstrictions.
    Chignard M; Lefort J; Vargaftig BB
    Agents Actions Suppl; 1979; (6):105-11. PubMed ID: 118655
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacology of prostacyclin].
    Imai S
    Kokyu To Junkan; 1985 Jul; 33(7):845-9. PubMed ID: 2997894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.